Earnings summaries and quarterly performance for Enovis.
Executive leadership at Enovis.
Board of directors at Enovis.
Research analysts who have asked questions during Enovis earnings calls.
CC
Caitlin Cronin
Canaccord Genuity
4 questions for ENOV
Also covers: ATEC, AXGN, BVS +10 more
DA
Danielle Antalffy
UBS Group AG
4 questions for ENOV
Also covers: ABT, ATRC, BAX +15 more
Vijay Kumar
Evercore ISI
4 questions for ENOV
Also covers: A, ABT, AVTR +21 more
RM
Robert Marcus
JPMorgan Chase & Co.
3 questions for ENOV
Also covers: ABT, BAX, BDX +21 more
VC
Vikramjeet Chopra
Wells Fargo & Company
3 questions for ENOV
Also covers: ALGN, ATEC, CNMD +9 more
YL
Young Li
Jefferies
3 questions for ENOV
Also covers: ALC, ARAY, ATEC +8 more
BV
Brandon Vazquez
William Blair & Company, L.L.C.
2 questions for ENOV
Also covers: ALGN, CBLL, CVRX +16 more
DR
Dane Reinhardt
Robert W. Baird & Co.
2 questions for ENOV
Also covers: INMD
Jeffrey Johnson
Robert W. Baird & Co. Inc.
2 questions for ENOV
Also covers: ALC, ALGN, BBNX +11 more
Michael Matson
Needham & Company
2 questions for ENOV
Also covers: AORT, ATRC, CNMD +22 more
Russell Yuen
William Blair & Company
2 questions for ENOV
Also covers: ALGN, NVST
JW
Jason Wittes
Roth Capital Partners, LLC
1 question for ENOV
Also covers: ALUR, ARAY, ATEC +13 more
Joseph Conway
Needham & Company, LLC
1 question for ENOV
Also covers: AORT, ATRC, HOLX +6 more
Mike Matson
Needham & Company, LLC
1 question for ENOV
Also covers: CNMD, ESTA, HAE +16 more
VC
Vik Chopra
Wells Fargo & Company
1 question for ENOV
Also covers: ALGN, ATEC, CNMD +7 more
Recent press releases and 8-K filings for ENOV.
ENvue Medical's UroShield Kit Secures UK Reimbursement
ENOV
New Projects/Investments
Revenue Acceleration/Inflection
- ENvue Medical's UroShield® Kit has been added to the UK National Health Service (NHS) Drug Tariff Part IX, allowing for nationwide prescription reimbursement across the UK.
- This reimbursement milestone is accompanied by an initial purchase order from Peak Medical, a leading UK distributor, indicating early commercial demand.
- The inclusion in the Drug Tariff removes a significant reimbursement barrier, enabling scalable NHS prescribing and providing early revenue visibility for 2026.
- UroShield® is a non-invasive device designed to reduce catheter-associated urinary tract infections (CAUTIs) and catheter blockages by applying low-frequency ultrasonic energy.
Dec 18, 2025, 2:00 PM
ENvue Medical Appoints New Chairman of the Board
ENOV
Board Change
Hiring
New Projects/Investments
- ENvue Medical has appointed David Johnson as its new Chairman of the Board.
- Mr. Johnson is a veteran healthcare executive with over 30 years of experience in medical technology and biotechnology, having held chairman roles at other companies and played a leadership role in a $4.1 billion sale.
- The company's FDA 510(k)-cleared feeding-tube placement system is currently utilized in 38 US hospitals, with plans for increased adoption in 2026 and expansion into neonatal and pediatric populations.
- Johnson's appointment is expected to support disciplined commercial expansion, broader hospital adoption, and continued platform development for ENvue Medical.
Dec 15, 2025, 2:00 PM
Enovis Amends Credit Agreement, Extends Maturity Date
ENOV
Debt Issuance
New Projects/Investments
- Enovis Corporation entered into Amendment No. 3 to its Credit Agreement on December 8, 2025, establishing a $1.1 billion revolving credit facility and a $700.0 million term loan facility.
- The maturity date for all outstanding Revolving Loans and Term Loans was extended to December 8, 2030.
- The amendment modified financial covenants, including lowering the acquisition threshold for a temporary increase in the maximum Senior Secured Leverage Ratio to $300.0 million (from $500.0 million) and increasing the cash offset for leverage ratio calculations to $400.0 million (from $150.0 million).
- The maximum consideration for a permitted acquisition was increased from $150.0 million to $200.0 million.
Dec 10, 2025, 11:30 AM
Enovis Discusses Strategic Focus, Growth Drivers, and Financial Goals at Jefferies Conference
ENOV
CEO Change
M&A
Guidance Update
- Damien McDonald, Enovis's newly appointed CEO, shared positive impressions of the company's strong product portfolio and talent, while highlighting the embedding of the Enovis Growth Excellence business system as a key opportunity.
- The company is actively shaping its portfolio, including the sale of the Dr. Comfort foot care business to improve capital allocation and debt reduction, which is expected to be accretive to the PNR business's growth and margin.
- Enovis is targeting high single-digit consistent top-line growth, annual margin expansion of at least 50 basis points, and free cash flow conversion of 70%-80%.
- Key growth drivers include 6%-7% implant growth in hips and knees, double-digit growth in shoulder and foot & ankle, and significant international expansion (nearly 50% of sales from 22%) following the LEMA integration.
- The company has reduced its leverage from 3.5 to 3.2 and aims to achieve sub-3 leverage in the near term.
Nov 18, 2025, 3:30 PM
Enovis Management Discusses Strategic Focus, Financial Goals, and Product Pipeline at Jefferies Conference
ENOV
Guidance Update
M&A
Product Launch
- Enovis's CEO, Damien McDonald, shared positive impressions regarding the company's strong product perception and talent, while identifying the deeper embedding of the Enovis Growth Excellence business system as a key opportunity.
- The company's strategic focus centers on commercial excellence, operational excellence, and disciplined capital allocation, highlighted by the Dr. Comfort divestiture, which was accretive to the PNR business's growth and margin and contributed to debt reduction.
- Enovis aims for high single-digit consistent top-line growth, annual margin expansion of at least 50 basis points, and free cash flow conversion up to 70-80%.
- The company has successfully reduced its leverage from 3.5 to 3.2 and is targeting a further reduction to sub-3 in the near term.
- Key product developments include the Ultamate Reverse Shoulder, which is in its early launch phase with a multi-year growth tailwind, and the Arvis Gen 2 AR headset, anticipated for a wider launch in the first half of next year.
Nov 18, 2025, 3:30 PM
Enovis Management Discusses Strategic Priorities, Portfolio Shaping, and Financial Goals at Jefferies Conference
ENOV
CEO Change
M&A
Product Launch
- CEO Damien McDonald, who joined mid-year, shared positive impressions of Enovis's product strength and talent, identifying an opportunity to further embed the Enovis Growth Excellence business system.
- The company is strategically shaping its portfolio, having divested the Dr. Comfort foot care business to reduce debt and enhance PNR's growth and margin. The portfolio is viewed as synergistic, with cash-generating PNR supporting the capital-intensive Recon business, aiming for a balanced mix in Recon (50% extremities, 50% large joints; 50% U.S., OUS).
- Enovis reported solid Ortho market procedural volumes for the current quarter, with U.S. hip and knee implants growing 6% (above market) despite a $3 million headwind from prior year capital sales, and double-digit growth in shoulder and foot and ankle.
- Innovation continues with key product launches like the Ultamate Reverse Shoulder (in its first year of a multi-year run) and the upcoming Arvis Gen 2 AR headset, which is a zero-footprint, low-cost alternative for surgical planning and navigation. These new products are expected to contribute to margin expansion.
- Financial goals include achieving high single-digit consistent top-line growth, expanding margins by at least 50 basis points annually, and reaching 70-80% free cash flow conversion. Leverage has been reduced from 3.5x to 3.2x, with a near-term target of sub-3x.
Nov 18, 2025, 3:30 PM
Enovis Outlines Strategic Priorities, Product Pipeline, and Financial Goals
ENOV
M&A
Product Launch
New Projects/Investments
- Enovis is currently focused on integrating the Lima acquisition, improving free cash flow generation (aiming for 70-80% conversion), and reducing its leverage ratio to under 3.0 from the current 3.2 before pursuing further strategic M&A.
- The company expects Arvis, a spatial navigation system for knees and shoulders, to be a significant tailwind, with a broader release planned for the first half of 2026.
- Enovis is seeing strong performance in its shoulder segment, with the augmented glenoid (ARG) product growing double digits through nine months, and is leveraging its market position in shoulder to gain share in hip and knee.
- The PNR business, while lower-growth, is a high cash flow generator that funds innovation in the capital-intensive recon business and has shown 110 basis points of gross margin improvement in the last quarter due to the application of the EGX business system.
Nov 10, 2025, 7:45 PM
Enovis Reports Strong Q3 2025 Results and Raises Full Year Guidance
ENOV
Earnings
Guidance Update
M&A
- Enovis reported Q3 2025 Net Sales of $549 Million, reflecting 9% reported growth and 7% organic growth, with Adjusted EPS reaching $0.75.
- The company generated approximately $30 Million in Free Cash Flow during Q3 2025, indicating improving cash generation.
- Enovis updated its Full Year 2025 outlook, raising guidance for aEBITDA to $395-$405 Million and aEPS to $3.10-$3.25.
- A divestiture of the Diabetic Footwear business, with a total transaction value of up to $60 Million and an upfront cash payment of $45 Million, is effective Q4 2025 and is expected to impact Q4 2025 revenue guidance by approximately ($15 Million).
Nov 6, 2025, 1:30 PM
Enovis Reports Q3 2025 Financial Results and Updates Full-Year Guidance
ENOV
Earnings
Guidance Update
M&A
- Enovis reported Q3 2025 sales of $549 million, marking a 9% reported and 7% organic growth, with strong performance in its recon business which grew 9% organically.
- The company completed the divestiture of its Doctor Comfort business in early October for up to $60 million, using $45 million in upfront cash to reduce debt and sharpen its focus on core markets.
- Full-year 2025 guidance was updated, with revenue adjusted to $2.24-$2.27 billion, adjusted EBITDA raised to $395-$405 million, and adjusted EPS increased by $0.05 to $3.10-$3.25.
- A non-cash technical impairment of goodwill totaling $548 million was recorded in Q3 2025 due to a sustained decline in share price, though it does not affect liquidity or future operations.
- Key product developments include the next-generation ARVIS Ultra system tracking for a broader launch in the first half of 2026, and new products like Nebula Stem and OrthoDrive Impactor performing well.
Nov 6, 2025, 1:30 PM
Enovis Announces Third Quarter 2025 Results and Updates Full-Year Guidance
ENOV
Earnings
Guidance Update
M&A
- Enovis reported net sales of $549 million for the third quarter of 2025, marking a 9% increase on a reported basis and 7% organically compared to the same period in 2024.
- The company posted a net loss of $571 million, or $9.99 per share, primarily due to a non-cash goodwill impairment charge of $548 million. Despite this, adjusted net earnings per diluted share were $0.75 and adjusted EBITDA was $95 million.
- In October 2025, Enovis completed the divestiture of its Diabetic Footcare business unit for up to $60 million, which resulted in a $15 million revenue reduction in the updated 2025 guidance.
- Enovis raised its full-year 2025 guidance for adjusted EBITDA to $395-405 million (from $392-402 million) and adjusted EPS to $3.10-3.25 (from $3.05-3.20). Revenue guidance was updated to $2.24-2.27 billion.
Nov 6, 2025, 11:09 AM
Quarterly earnings call transcripts for Enovis.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more